NPC-9901
Regimen
- Experimental
- Concurrent cisplatin 100 mg/m² q3w ×3 + RT, followed by adjuvant cisplatin 80 mg/m² + 5-FU ×3 cycles
- Control
- Radiotherapy alone
Population
T1-4N2-3M0 non-keratinizing/undifferentiated NPC (advanced nodal disease), Hong Kong centres
Key finding
Hong Kong confirmation of INT-0099 in the largest single Asian CCRT RCT at the time (N=348). Demonstrated significant failure-free and locoregional control improvement, though overall survival at 3 years was paradoxically identical (78% both arms) — attributed to salvage effectiveness and short follow-up. The nodal-advanced eligibility criterion (N2-3) specifically targeted the highest-risk subset in endemic NPC. Follow-up data later showed OS benefit at 5 and 10 years.
Source: PMID 16192584